Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Editas Medicine Inc chart...

About the Company

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

$255M

Total Revenue

297

Employees

$631M

Market Capitalization

-3.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EDIT News

Insider Sells Shares of Editas Medicine Inc (EDIT)

13d ago, source:

Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript

18d ago, source: Hosted on MSN

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.

Editas Medicine, Inc. (NASDAQ:EDIT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

17d ago, source: Yahoo Finance

Editas Medicine, Inc. (NASDAQ:EDIT) just released its latest full-year results and things are looking bullish. Revenues of US$78m beat estimates by a substantial 177% margin. Unfortunately ...

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

18d ago, source: Hosted on MSN

Editas Medicine, Inc.EDIT incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of ...

Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

5d ago, source: Seeking Alpha

My name is Gena Wang. I cover the US mid-cap biotech. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us today we have Gilmore O'Neil, Chief Executive ...

Editas Medicine files patent for genome editing system components using engineered nucleic acids

6d ago, source: Pharmaceutical Technology

Discover how Editas Medicine Inc. is revolutionizing genome editing with their patented engineered nucleic acids and RNA-guided nucleases. Explore the innovative Cpf1 protein technology outlined in ...

Why Editas Medicine Stock Soared as Much as 42% Higher This Week

on MSN ago, source:

Shares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence. By the time the market closed on Friday, the ...

Editas Medicine Inc 8EM

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript

19d ago, source: Seeking Alpha

Good morning, and welcome to Editas Medicine's Fourth Quarter and Full Year 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript

19d ago, source: Insider Monkey

Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52. EDIT isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...